

GLAXOSMITHKLINE PLC
Form 6-K
August 08, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 08 August 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

Details of PDMR/person closely associated with
1. them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/
amendment Initial notification

Details of the issuer, emission allowance market
2. participant, auction platform, auctioneer or auction
monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated
3. for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transaction(s) has been conducted

- a) Description Ordinary shares of 25 pence
of each ('Ordinary Shares')
the ISIN: GB0009252882
financial instrument

- b) Nature of the transaction Sale of Ordinary Shares

- c) Price(s) and volume(s) Price(s) Volume(s)
£15.9462 40,000

- d) Aggregated information n/a (single transaction)

- d) Aggregated volume Price

- e) Date of the 2018-08-07

transaction

f) Place
of the transaction London Stock Exchange
(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: August 8, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc